Hot Investor Mandate: Large China VC with Recently Launched Healthcare Fund Seeks to Invests Up to $15M in Early-Stage Therapeutics, Medical Devices, Diagnostics, and Digital Health

13 Sep

A venture capital firm founded in China has over $4 billion in total managed assets in the areas of healthcare, technology and internet, and clean tech. The firm has invested in more than 70 healthcare companies that span most sectors of life sciences from pharmaceuticals and medical devices to healthcare IT, diagnostics and select healthcare services.

The firm closed their healthcare fund in early 2018, focused on early-stage health care opportunities in the US with potential market opportunities in China. The firm has USA operations in both the West and East Coast. The firm intends to lead, co-lead, or co-invest in US-based private companies in biotech for therapeutics, medtech, and digital health technologies, with equity investments ranging from $5 to $15 million. The firm will not make public company investments.

The firm is open to many sectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm seeks investments in 510K devices and will invest in devices in the PMA pathway depending on stage, preferably clinical or later. In therapeutics, the firm is modality-agnostic but generally seeking opportunities that are past the pre-clinical stage. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. Given the firm’s slogan of “inspiring people with the wisdom to succeed with diligence,” The firm’s team is “hands-on” and typically assumes a board seat after an investment. Investments in US companies are expected to have upside opportunities in China and can leverage the firm’s China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: